Author:
Wang Xiaochuan,Zhang Yu,Ji Zhengguo,Yang Peiqian,Tian Ye
Abstract
Abstract
Background
To evaluate the predictive performance of age for the risk of Gleason score change and pathologic upstaging.
Evidence acquisition
Ovid MEDLINE, Ovid Embase, and the Cochrane Library were searched from inception until May 2020. Quality of included studies was appraised utilizing the Newcastle-Ottawa Quality Assessment Scale for case-control studies. The publication bias was evaluated by funnel plots and Egger’s tests.
Evidence synthesis
Our search yielded 27 studies with moderate-to-high quality including 84296 patients with mean age of 62.1 years. From biopsy to prostatectomy, upgrading and upstaging occurred in 32.3% and 9.8% of patients, respectively. Upgrading from diagnostic biopsy to confirmatory biopsy was found in 16.8%. Older age was associated with a significant increased risk of upgrading (OR 1.04, 95% CI 1.03–1.05), and similar direction of effect was found in studies focused on upgrading from diagnostic biopsy to confirmatory biopsy (OR 1.06, 95% CI 1.04–1.08). For pathologic upstaging within older men compared with younger, the pooled odds was 1.03 (95% CI 1.01–1.04).
Conclusion
Thorough consideration of age in the context of effect sizes for other factors not only prompts more accurate risk stratification but also helps providers to select optimal therapies for patients with prostate cancer.
Publisher
Springer Science and Business Media LLC
Reference46 articles.
1. Mottet N, Cornford P, van den Bergh RCN, et al. EAU - EANM -ESTRO - ESUR - SIOG guidelines on prostate cancer. Arnhem, The Netherlands: European Association of Urology Guidelines Office; 2020.
2. Fenton JJ, Weyrich MS, Durbin S, et al. Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the us preventive services task force. JAMA. 2018;319:1914–31.
3. Johansson JE, Holmberg L, Johansson S, et al. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA. 1997;277:467–71.
4. Cohen MS, Hanley RS, Kurteva T, et al. Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic, Medical Center experience and an international meta-analysis. Eur Urol. 2008;54:371–81.
5. Morlacco A, Cheville JC, Rangel LJ, et al. Adverse disease features in Gleason score 3 + 4 “favorable intermediate-risk”prostate cancer: implications for active surveillance. Eur Urol. 2016;72:442–7.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献